- Home
- PIII vs IXHL Comparison
PIII vs IXHL Comparison
Compare PIII & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- IXHL
- Stock Information
- Founded
- PIII 2015
- IXHL 2001
- Country
- PIII United States
- IXHL Australia
- Employees
- PIII N/A
- IXHL N/A
- Industry
- PIII Medical/Nursing Services
- IXHL
- Sector
- PIII Health Care
- IXHL
- Exchange
- PIII Nasdaq
- IXHL Nasdaq
- Market Cap
- PIII 21.4M
- IXHL 20.5M
- IPO Year
- PIII N/A
- IXHL N/A
- Fundamental
- Price
- PIII $6.37
- IXHL $0.21
- Analyst Decision
- PIII Buy
- IXHL
- Analyst Count
- PIII 2
- IXHL 0
- Target Price
- PIII $16.25
- IXHL N/A
- AVG Volume (30 Days)
- PIII 5.1K
- IXHL 35.9M
- Earning Date
- PIII 08-06-2025
- IXHL 05-15-2025
- Dividend Yield
- PIII N/A
- IXHL N/A
- EPS Growth
- PIII N/A
- IXHL N/A
- EPS
- PIII N/A
- IXHL N/A
- Revenue
- PIII $1,485,192,000.00
- IXHL $98,000.00
- Revenue This Year
- PIII N/A
- IXHL $3,817.06
- Revenue Next Year
- PIII $6.01
- IXHL $66.67
- P/E Ratio
- PIII N/A
- IXHL N/A
- Revenue Growth
- PIII 9.79
- IXHL N/A
- 52 Week Low
- PIII $6.00
- IXHL $0.08
- 52 Week High
- PIII $32.54
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- PIII 33.55
- IXHL 45.47
- Support Level
- PIII $6.00
- IXHL $0.20
- Resistance Level
- PIII $6.35
- IXHL $0.23
- Average True Range (ATR)
- PIII 0.22
- IXHL 0.02
- MACD
- PIII 0.03
- IXHL 0.01
- Stochastic Oscillator
- PIII 21.62
- IXHL 33.30
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.